| INTRODUCTION
More than 91 000 people were diagnosed with cutaneous melanoma in the United States (US) in 2018. In the same period, melanoma was associated with over 9000 deaths. 1 Although cutaneous melanoma currently represents 1.5% of all cancer deaths, the NCI/SEER database notes a 50% increase in US melanoma incidence during the past 20 years, from 15 per 100 000 population per year to 22.8 per 100 000 per year. 2 Ten-year survival is now greater than 95% for those with thin nonulcerated melanomas and negative nodes. However, by the time the disease becomes increasingly penetrative of the skin and/or develops local ulceration, 10-year survival rates may be as low as 40%, even with negative nodes. 3 Although the clinicopathologic features of melanoma provide useful information about overall risk, they provide more limited information about outcomes in individual patients.
The recent development of effective systemic drug therapy for melanoma has significantly changed patient management and outcomes, particularly in more advanced disease. In this review, we will explore the development and validation of a variety of putative prognostic tumor biomarkers and biomarker panels in cutaneous melanoma. We will explore the issues of prognosis and prediction, and will highlight the importance of validation in the assessment of any biomarker assay. Finally, we will review the level of evidence (LOE) that might support the clinical incorporation of any of these tests into standard clinical practice.
| CLINICOPATHOLOGIC FEATURES FOR RISK ASSESSMENT
Pathologic features have been the basis of cutaneous melanoma prognosis and staging for nearly 40 years. 9 Clark and Breslow each described features of primary melanoma invasion in the early 1970s that became incorporated into the American Joint Committee on Cancer (AJCC) 1st Edition Staging Manual, published in 1977. 10, 11 Additional features were added over the years, with modification of various T-stage cutoffs. The Clark levels were ultimately discarded from AJCC staging and have become of largely historic interest. 3, 12, 13 The AJCC 8th Edition Staging Manual now assesses early stage disease based only on Breslow thickness, ulceration, and lymph node status. The most recent National Comprehensive Cancer Network (NCCN) Guidelines document identifies elements of a primary lesion that must be included in the pathology report. These are Breslow thickness (mm), ulceration, and microsatellite metastasis. Additional factors of prognostic relevance recommended for inclusion in the pathology report are dermal mitotic rate (per mm 2 ), lymphovascular invasion, and peripheral and deep margins (Table 1 ). [14] [15] [16] [17] [18] The American Academy of Dermatology (AAD) suggests addi- SLNBx. This study found no difference in MSS or distant metastasisfree survival (DMFS) between patients in either of the randomized treatment arms. 38 There was a slight but significant improvement in disease free survival (DFS) at 3 years (68% ± 1.7% and 63% ± 1.7%, respectively; P = 0.05 by the log-rank test), and DFS in regional nodes (92% ± 1.0%, and 77% ± 1.5%, respectively; P < 0.001 by the log-rank test). Based on the information available, there is no evidence that recognized prognostic indicators affected these findings. 
| Prognostic biomarkers in melanoma
Estimating the risk of metastasis and/or survival associated with early stage melanoma is a clinical challenge. As described above, two out of three early-stage patients who die from melanoma are initially diagnosed with stage I or II disease. 36 Biomarkers for early stage melanoma prognosis and prediction span protein, nucleic acid, and metabolic molecules, but the molecular markers that have been successfully translated to the clinic are primarily nucleic acids, likely due to rapid and reproducible results. The development of robust methods for purifying RNA from FFPE tumor tissue, the standard preservation method implemented for primary melanoma tumors, has allowed for the discovery of multiplexed markers associated with prognostication of sentinel lymph node status, locoregional recurrences, distant metastases, and survival. Gene expression profiling (GEP) has subsequently advanced to the clinical setting to inform patient management decisions. This section reviews the single and multimarker assays that have been developed for the purpose of identifying patients who have low-risk disease according to standard staging criteria, but potentially harbor more aggressive tumors.
| Protein biomarkers
Although a great amount of research effort has been focused on the discovery of proteins associated with melanoma prognosis ( However, broader validation of these markers, particularly for early stage melanoma, has not been achieved.
| Single gene biomarkers
Perhaps due to the ease with which multimarker gene panels can be 
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Unlike other cancer types, there are no independent genomic markers that are currently recommended for melanoma prognosis by the NCCN or included as part of the AJCC 8th Edition staging system.
| Multiplexed prognostic biomarkers
GEP technology is well suited for prognosis of early stage melanoma.
RT-PCR technology is an analytically robust and reproducible platform able to simultaneously evaluate many genes representing multiple cellular pathways. Four prognostic GEP signatures have been reported in the literature, with varying degrees of evidence supporting their utility for informing decisions about patient management (Table 3) . [55] [56] [57] [58] The first to appear in published literature was a nine-gene signature from
Brunner and colleagues, discovered from analysis of 92 candidate genes previously shown by microarray analysis to be differentially expressed in correlation with overall survival. 55 Of note, fresh-frozen primary tumor 
T A B L E 3 Multiplexed prognostic gene expression profile tests in cutaneous melanoma

Prognostic marker Evidence summary Evidence type References
DecisionDx-Melanoma (31-GEP) Consistent evidence supports independent prognostic value across multiple prospective and retrospective validation studies; utility for impacting patient management in prospective and retrospective studies; robust analytic validity CV, CU, AV Gastman et al 71 Greenhaw et al 69 Dillon et al 73 Hsueh et al 70 Cook et al 68 Berger Genes included in the 31-GEP were distilled from a comparative review of multimarker studies performed between 2000 and 2011, from which over 150 genes associated with recurrence were identified. [61] [62] [63] [64] [65] RFS rates of 77% in a cohort 1.5 years median follow up. [69] [70] [71] In addition to clinical and analytic validity studies, the clinical utility of the 31-GEP has been assessed in prospectively and retrospectively designed studies. [72] [73] [74] An important utility of the test is its use in risk- The group demonstrated the significant correlation of the GEP with best overall response rate and progression-free survival in patients enrolled in the KEYNOTE studies who were treated with pembrolizumab. 92 The group further refined the GEP to 18 genes that were (Table 4) . Reports suggest that MSI is detected in nearly a third of primary melanoma tumors. 93 However, MSI is further divided into MSI-high and MSI-low categories. The majority of melanoma tumors are expected to be MSI-low, as a recent report found that only 0.64% of tumors were MSI-high. 94 Thus, the clinical application for melanoma patients is still in question. This population gives rise to the majority of melanoma deaths among patients presenting with early-stage disease.
| Predictive biomarkers in melanoma
| Protein biomarkers
Clearly there needs to be more development and integration of predictive biomarkers and/or biomarker panels for therapeutic decision-making in early stage melanoma. The ability to precisely assess and target risk of recurrence is at the core of precision medicine and is critical to take full advantage of the evolving tools to treat malignant cutaneous melanoma. 
| CONCLUSIONS
